PubRank

Kazuyasu Sakaguchi

Author PubWeight™ 20.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle 2009 1.57
2 Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol 2007 1.39
3 Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol 2002 1.03
4 PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J Biochem 2008 1.03
5 Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J Mol Biol 2007 1.01
6 Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry 2006 0.98
7 SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription. J Mol Biol 2009 0.96
8 Thr-774 (transmembrane segment M5), Val-920 (M8), and Glu-954 (M9) are involved in Na+ transport, and Gln-923 (M8) is essential for Na,K-ATPase activity. J Biol Chem 2005 0.93
9 Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide. J Med Chem 2010 0.89
10 A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg Med Chem Lett 2011 0.86
11 Effect of phosphorylation on the structure and fold of transactivation domain of p53. J Biol Chem 2002 0.85
12 Evidence for a relationship between activity and the tetraprotomeric assembly of solubilized pig gastric H/K-ATPase. J Biochem 2005 0.82
13 Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Protein Pept Lett 2008 0.82
14 Evaluation of transcriptional activity of p53 in individual living mammalian cells. Anal Biochem 2009 0.81
15 Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure. Biopolymers 2009 0.81
16 Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem 2010 0.80
17 Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives. Bioorg Med Chem Lett 2010 0.80
18 Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors. Bioorg Med Chem 2009 0.78
19 Drastic effects on fibril formation of amyloid-beta peptides by the addition of amino acid residue units to the termini. Protein Pept Lett 2010 0.77
20 Effects of biomineralization peptide topology on the structure and catalytic activity of Pd nanomaterials. Chem Commun (Camb) 2014 0.76
21 Structural isoforms of the circadian neuropeptide PDF expressed in the optic lobes of the cricket Gryllus bimaculatus: immunocytochemical evidence from specific monoclonal antibodies. J Comp Neurol 2006 0.76
22 Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody. J Biochem 2011 0.76
23 Probing phenylalanine environments in oligomeric structures with pentafluorophenylalanine and cyclohexylalanine. Biopolymers 2011 0.75
24 [Tetramerization of tumor suppressor protein p53]. Seikagaku 2010 0.75
25 New evidence for ATP binding induced catalytic subunit interactions in pig kidney Na/K-ATPase. J Biochem 2006 0.75
26 Inhibition of tumor suppressor protein p53-dependent transcription by a tetramerization domain peptide via hetero-oligomerization. Bioorg Med Chem Lett 2012 0.75
27 Effects of tumor-associated mutations in the p53 tetramerization domain on oligomerization state and transcriptional activity. Adv Exp Med Biol 2009 0.75
28 [Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy]. Seikagaku 2015 0.75
29 Formation process and solvent-dependent structure of a polyproline self-assembled monolayer on a gold surface. Langmuir 2011 0.75
30 Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding. J Pept Sci 2002 0.75